Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT307 in Advanced Solid Tumors
NCT07534813Withdrawn
- Sponsor
- Grit Biotechnology
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT307 in solid tumor (advanced stage), sponsored by Grit Biotechnology. Primary endpoints: Evaluation of the safety of GT307 at 24 months and Evaluation of the tolerability of GT307 at 24 months. Planned start Apr 2026; status: withdrawn.
02
Drugs
GT307
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07534813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07534813.